文献速递肺结节与肺癌

围手术期替雷利珠单抗联合新辅助化疗治疗可切除非小细胞肺癌(RATIONALE-315)的期中分析

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.
PubMed 文献 · Lancet Respir Med · 2024-11-21

RATIONALE-315是一项在中国50家中心开展的随机双盲安慰剂对照3期试验,纳入453例未经治疗的II-IIIA期可切除NSCLC患者,1:1随机接受新辅助替雷利珠单抗或安慰剂联合铂类双药化疗,术后辅助替雷利珠单抗或安慰剂。

要点

  • 替雷利珠单抗组主要病理缓解率56%,安慰剂组15%,差异41%(95%CI 33-49)。
  • 替雷利珠单抗组3级及以上不良事件发生率72%,安慰剂组66%。

核心结论

  • 围手术期替雷利珠单抗联合新辅助化疗较单纯新辅助化疗在可切除II-IIIA期NSCLC中显示出临床意义且统计学显著的有效性改善,安全性可控。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验,在中国50家中心开展,共纳入453例未经治疗的II-IIIA期鳞状或非鳞状NSCLC患者,1:1随机分组。
  • 双主要终点为主要病理缓解率和无事件生存期,按意向治疗分析;安全性在至少接受一剂研究治疗的患者中评估。

主要发现

  • 替雷利珠单抗组3级及以上不良事件发生163例(72%),严重治疗相关不良事件35例(15%);安慰剂组分别为150例(66%)和18例(8%)。
  • 最常见的3级及以上治疗相关不良事件为中性粒细胞计数降低,替雷利珠单抗组138例(61%),安慰剂组134例(59%)。
  • 替雷利珠单抗组31例(14%)死亡,安慰剂组45例(20%)死亡。

关键数值与推荐

  • 3级及以上不良事件:替雷利珠单抗组72%(163/226)vs 安慰剂组66%(150/226)。
  • 严重治疗相关不良事件:替雷利珠单抗组15%(35/226)vs 安慰剂组8%(18/226)。

临床怎么用

  • 对于可切除II-IIIA期NSCLC患者,可考虑围手术期替雷利珠单抗联合新辅助化疗及术后辅助替雷利珠单抗治疗。
  • 治疗期间需关注3级及以上不良事件,尤其是中性粒细胞计数降低,并监测严重治疗相关不良事件。

局限性

  • 本次报告为期中分析,无事件生存期数据尚未成熟。
  • 研究仅在中国进行,人群以男性为主(91%),外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment guidelines recommend neoadjuvant or adjuvant chemotherapy, with or without immune checkpoint inhibitors, for resectable non-small-cell lung cancer (NSCLC). We report the interim results for the phase 3 RATIONALE-315 study, which aimed to investigate perioperative tislelizumab for the treatment of resectable NSCLC. METHODS: RATIONALE-315 is a randomised, double-blind, placebo-controlled phase 3 trial conducted at 50 sites (hospitals or academic research centres) in China. Patients (aged ≥18 years) with untreated stage II-IIIA squamous or non-squamous NSCLC were randomly assigned (1:1) to neoadjuvant tislelizumab 200 mg or placebo intravenously every 3 weeks, plus platinum-based doublet chemotherapy followed by surgery and adjuvant tislelizumab 400 mg or placebo every 6 weeks. Dual primary endpoints were major pathological response rate and event-free survival, analysed by intention to treat. Safety was also assessed in all patients who received at least one dose of study treatment. RATIONALE-315 is registered with ClinicalTrials.gov, NCT04379635, and is active but not recruiting. FINDINGS: Between June 8, 2020, and Aug 31, 2022, 453 patients were assigned to tislelizumab (n=226) or placebo (n=227). The median age of patients was 62·0 years (IQR 56·0-67·0). 410 (91%) of 453 patients were male and 43 (9%) were female. As of Aug 21, 2023 (data cutoff for the interim analysis of event-free survival), median duration of follow-up was 22·0 months (IQR 15·5-28·0). Tislelizumab significantly improved event-free survival versus placebo (stratified hazard ratio 0·56 [95% CI 0·40-0·79]; one-sided p=0·0003). The major pathological response rate was significantly higher in the tislelizumab group (56% [95% CI 50-63]) than in the placebo group (15% [11-20]; difference 41% [33-49]; one-sided p<0·0001). Grade 3 or worse adverse events and serious treatment-related adverse events occurred in 163 (72%) of 226 patients and 35 (15%) of 226 patients, respectively, in the tislelizumab group, and in 150 (66%) and 18 (8%) patients, respectively, in the placebo group. The most common grade 3 or worse treatment-related adverse event was decreased neutrophil count (138 [61%] of 226 in the tislelizumab group vs 134 [59%] of 226 in the placebo group). 31 (14%) of 226 patients in the tislelizumab group and 45 (20%) of 227 patients in the placebo group died during the study. INTERPRETATION: Perioperative tislelizumab plus neoadjuvant chemotherapy showed a clinically meaningful and statistically significant improvement in efficacy and a manageable safety profile compared with neoadjuvant chemotherapy in patients with resectable stage II-IIIA NSCLC. FUNDING: BeiGene.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Yue D, Wang W, Liu H, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2024. PMID: 39581197. doi:10.1016/S2213-2600(24)00269-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。